UroGen Pharma URGN Noncash Inprocess Research And Development Expense
Noncash Inprocess Research And Development Expense at other companies
Other financials
Where this comes from
Reported directly by UroGen Pharma in its filing.
Tagged under the XBRL concept urgn:NoncashInprocessResearchAndDevelopmentExpense.
The official record: UroGen Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about UroGen Pharma's noncash inprocess research and development expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is UroGen Pharma's noncash inprocess research and development expense?
- UroGen Pharma (URGN) reported noncash inprocess research and development expense of $0 in Q1 2026.
- How has UroGen Pharma's noncash inprocess research and development expense changed year-over-year?
- UroGen Pharma's noncash inprocess research and development expense decreased by 100.0% year-over-year, from $3.13M to $0.
- What does noncash inprocess research and development expense mean?
- Captures the non-cash portion of expenses related to acquired in-process research and development projects, often resulting from accounting adjustments or non-monetary consideration. It highlights the accounting impact of innovation-focused investments that do not directly affect current period cash flow.